Brain Cancer – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23050IDB-L5

Select Item

Empower your strategies with our Brain Cancer – Drugs In Development, 2024 report and make more profitable business decisions.

Brain cancer refers to the abnormal growth of cells in the brain, forming tumors that can be benign (non-cancerous) or malignant (cancerous). Primary brain tumors originate in the brain itself, while secondary tumors result from the spread of cancer from other parts of the body. Symptoms may include headaches, seizures, changes in behavior, and cognitive impairment. Diagnosis involves imaging studies like MRI or CT scans, and treatment options vary depending on the tumor type, location, and grade. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these. Prognosis and outcomes depend on factors like tumor type, stage, and the effectiveness of treatment.

The Brain Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Cancer and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Brain Cancer
Key Targets
· Cyclin Dependent Kinase 4; Cyclin Dependent Kinase 6; Epidermal Growth Factor Receptor ERB1; Smoothened Homolog; Receptor Tyrosine Protein Kinase ERBB 2; DNA Topoisomerase I; Signal Transducer And Activator Of Transcription 3; Tubulin ; DNA; and CD3
Key Mechanisms of Action
· Cyclin Dependent Kinase 4 Inhibitor; Cyclin Dependent Kinase 6 Inhibitor; Epidermal Growth Factor Receptor ERB1 Inhibitor; Smoothened Homolog Antagonist; Signal Transducer And Activator Of Transcription 3 Inhibitor; DNA Topoisomerase I Inhibitor; CD3 Agonist; Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor; Poly [ADP Ribose] Polymerase 1 Inhibitor; and Programmed Cell Death Protein 1 Antagonist
Key Routes of Administration
· Oral; Intravenous; Intratumor; Parenteral; Subcutaneous; Topical; Intradermal; Intraperitoneal; Intralesional; and Intracavitary
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Gene-Modified Cell Therapy; Cell Therapy; Oncolytic Virus; Subunit Vaccine; Synthetic Peptide; Peptide; Oligonucleotide; and Protein
Major Companies
· Bristol-Myers Squibb Co; Celprogen Inc; IMPACT Therapeutics Inc; Fulgent Pharma LLC; MacroGenics Inc; Mustang Bio Inc; Moleculin Biotech Inc; Neurxstem Inc; Yuhan Corp; and Segue Therapeutics LLC

Scope

  • Therapeutics in Development: Covering 138 molecules, with 119 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Brain Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Brain Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Brain Cancer treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Acrivon Therapeutics Inc
Actinium Pharmaceuticals Inc
AimedBio Inc
AntiRadical Therapeutics LLC
Arjuna Therapeutics
Aurigene Oncology Ltd
Bayer AG
Beijing zhikangbo Medical Oncology Research Co Ltd
Bellicum Pharmaceuticals Inc
Biodexa Pharmaceuticals PLC
Biogenera SpA
Boehringer Ingelheim International GmbH
BPGbio Inc
Bristol-Myers Squibb Co
Calviri Inc
Cancer Research UK
Cardiff Oncology Inc
Cellid Co Ltd
Celprogen Inc
Centessa Pharmaceuticals Plc
Chang Gung Memorial Foundation
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Chrysalis BioTherapeutics Inc
Cincinnati Children's Hospital Medical Center
Cotinga Pharmaceuticals Inc
Curasight
Curtana Pharmaceuticals Inc
Dalriada Therapeutics Inc
Disulfican Ltd
Dracen Pharmaceuticals Inc
Edison Oncology Holding Corp
Eisai Co Ltd
Elucida Oncology Inc
F. Hoffmann-La Roche Ltd
Gan & Lee Pharmaceuticals Co Ltd
Genentech USA Inc
General Hospital of the People's Liberation Army
Gennao Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
HB Therapeutics Inc
Hinova Pharmaceuticals Co Ltd
Hudson Institute of Medical Research
Immunomic Therapeutics Inc
ImmunSYS Inc
IMPACT Therapeutics Inc
Incanthera Plc
InnoBioPharma LLC
Institute of Biotechnology and Pharmaceutical Research
Istari Oncology Inc
Kintor Pharmaceutical Ltd
Komipharm International Co Ltd
Laevoroc Oncology AG
LIfT BioSciences Ltd
Lumos Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
McMaster University
MD2 Biosciences Inc
Medific Inc
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
N1 Life Inc
Nanjing KAEDI Biotech Inc
Nascent Biotech Inc
Natsar Pharmaceuticals Inc
Neonc Technologies Inc
Neurxstem Inc
Nino Jesus University Children's Hospital
Novartis AG
Noviga Research AB
Nurix Therapeutics Inc
Nuvectis Pharma Inc
OBI Pharma Inc
Ohio State University
Oncoheroes Biosciences Inc
OncoLife Therapeutics Pty Ltd
Oncorus Inc
Oncurious NV
Orphelia Pharma SAS
Orpheus Therapeutics Inc
Patrys Ltd
PENAO Pty Ltd
Pfizer Inc
PharmaEngine Inc
PNB Vesper Life Science Pvt Ltd
Progenics Pharmaceuticals Inc
ProLynx LLC
Quadriga BioSciences Inc
RefleXion Medical Inc
Res Nova Bio Inc
Revolution Medicines Inc
Sapience Therapeutics Inc
Seagen Inc
Segue Therapeutics LLC
Sequoia Vaccines Inc
Shionogi & Co Ltd
Splash Pharmaceuticals Inc
Stanford University
Stanford University School of Medicine
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology
Inc
Sumitomo Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Suntec Medical (Taiwan) Inc
Tasrif Pharmaceutical Inc
The Scripps Research Institute
Travecta Therapeutics Pte Ltd
Treovir LLC
University of Connecticut
University of Florida
University of North Carolina
University of Rochester
University of Utah
Urmia University of Medical Sciences
Vacino Biotech Co Ltd
Valo Health LLC
VBI Vaccines Inc
Viomedix LLC
Vyriad Inc
Vyro Bio Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Winship Cancer Institute of Emory University
Wuhan Binhui Biopharmaceutical Co Ltd
Yuhan Corp
Zelira Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Brain Cancer reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Brain Cancer – Drugs In Development, 2024 in real time.

  • Access a live Brain Cancer – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more